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Abstract
Bone marrow (BM) derived vascular precursor cells (BM-PC, endothelial progenitors) are involved in normal and malignant
angiogenesis, in ischemia and in wound healing. However, the mechanisms by which BM-PC stimulate the pre-existing
endothelial cells at sites of vascular remodelling/recovery, and their contribution towards the formation of new blood
vessels are still undisclosed. In the present report, we exploited the possibility that members of the Notch signalling
pathway, expressed by BM-PC during endothelial differentiation, might regulate their pro-angiogenic or pro-wound healing
properties. We demonstrate that Notch pathway modulates the adhesion of BM-PC to extracellular matrix (ECM) in vitro via
regulation of integrin alpha3beta1; and that Notch pathway inhibition on BM-PC impairs their capacity to stimulate
endothelial cell tube formation on matrigel and to promote endothelial monolayer recovery following wounding in vitro.
Moreover, we show that activation of Notch pathway on BM-PC improved wound healing in vivo through angiogenesis
induction. Conversely, inoculation of BM-PC pre-treated with a gamma secretase inhibitor (GSI) into wounded mice failed to
induce angiogenesis at the wound site and did not promote wound healing, presumably due to a lower frequency of BM-PC
at the wound area. Our data suggests that Notch pathway regulates BM-PC adhesion to ECM at sites of vascular repair and
that it also regulates the capacity of BM-PC to stimulate angiogenesis and to promote wound healing. Drug targeting of the
Notch pathway on BM-PC may thus represent a novel strategy to modulate neo-angiogenesis and vessel repair.
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Introduction
The vertebrate skin represents a major barrier against external
damage. Maintenance of a functional/undamaged skin namely
through an efficient cutaneous wound healing is essential.
Cutaneous wound healing involves an inflammatory response,
formation of granulation tissue, angiogenesis and tissue remodel-
ling [1,2]. During these processes there is interplay between
different cell types or between cells and the extracellular matrix
(ECM) which are mediated by chemokines/growth factors and
integrins, respectively. [3,4]. Angiogenesis, the process by which
new capillaries are formed, is a fundamental step in wound
healing. The formation of new vessels at the wound site allows the
inflammatory cells to migrate into the wound, but also supply the
oxygen and nutrients necessary to sustain the growth of the
granulation tissue and epidermis [5].
Bone marrow derived progenitor cells (BM-PC) with vasculo-
genesis/angiogenesis potential have been proven essential in a
variety of models of post-natal angiogenesis [6]. Despite the
heterogeneity of BM-PC populations, it is now accepted that bone
marrow derived endothelial progenitor cells (EPC) and bone
marrow derived mesenchymal stem cells (MSC) can enhance
angiogenesis and promote vascular healing in different models,
such as in cutaneous wound healing. Accordingly, it has been
shown that BM-PC can improve angiogenesis at the wound site by
differentiation and incorporation into mature vessels and produc-
tion of pro-angiogenic factors [7,8,9]. In addition, recruited BM-
PC may promote endothelial cell migration and proliferation via
the production of IL-8, VEGF, angiopoietin-1 or stromal derived
factor-1 (SDF-1), among other factors [10,11,12].
The Notch signalling pathway involves the activity of Notch
transmembrane receptors 1, 3 and 4, which interact with membrane-
bound ligands, Delta1, 2 and 4 and Serrate/Jagged 1 and 2. Ligand
binding induces proteolytic cleavage of Notch receptor by a gamma-
secretase complex causing the subsequent translocation of the Notch
intracellular domain (NICD) to the nucleus, where it will activate the
transcription of downstream target genes such as Hes1 (hairy
enhancer of split homolog-1) and Hey1 and Hey2 (Hes related
protein) [13]. Deficient Notch signalling impairs normal vascular
development in the embryo [14,15,16,17,18]. More recently
involvement of the Notch pathway in cutaneous wound healing
was demonstrated, since Notch antisense transgenic mice and normal
mice treated with gamma-secretase inhibitors have impaired healing
due to defective endothelial and keratinocyte cell migration [19].
However the contribution of BM-PC in these settings was not
addressed. Considering this, besides regulating arterial/venous fate
[20,21], the role of the N/D pathway in regulating BM-PC
differentiation and function during angiogenesis is still elusive.
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3752In the present study, we hypothesized that the Notch pathway
might be involved in the communication between recruited BM-
PC and endothelial cells during wound healing. To test this
hypothesis, we employed gamma-secretase inhibitors to block
Notch activity and overexpression of the Notch ligand Dll4 to
address how Notch signalling contributes to the function of BM-
PC in vitro and during the angiogenic response in cutaneous
wound healing.
Results
BM-derived progenitors express Delta-Notch members
and show evidence for Notch pathway activation in vitro
BM-PC (lin-sca1+) cells were cultured on endothelial-differen-
tiation medium and the expression of Delta-Notch members and
their target genes was determined by RT and semi-quantitative
(RQ) PCR, throughout endothelial differentiation. As shown in
Figure 1A, BM-PC express Delta-like 4, Delta 1 and Notch 1 but
do not express Notch 4. The expression of Notch downstream
target genes Hes 1, Hey 1 and Hey 2 increases throughout
endothelial differentiation (Figure 1B), as the majority of the
cultured cells differentiate and acquire endothelial markers and
properties (at day 20 of culture, Figure 1C and D and Figure S1).
These results suggest that BM-PC give rise to endothelial cells in
vitro and that this process is accompanied by activation of the
Notch signalling pathway and transcription of Notch target genes.
BM-PC adhesion to ECM in vitro is impaired by gamma-
secretase inhibition of Notch pathway and integrin
alpha3beta1 modulation
Having shown activation of Notch signalling on BM-PC under
endothelial differentiation conditions in vitro, we asked what aspect
of the endothelial differentiation process would be affected by
inhibiting the Notch pathway. As shown in Figure 2, Notch
pathway inhibition by a gamma-secretase-inhibitor (GSI, also
known as DAPT) reduced the activation of Notch target genes on
BM-PC (Fig 2A), impaired their adhesion to different ECM
components (Fig 2B,C,E) and reduced the percentage of
endothelial cells obtained under endothelial differentiation condi-
tions in vitro (Fig 2D). In contrast, transfection of BM-PC with a
constitutively active form of Notch4, to activate the Notch
pathway, promoted BM-PC adhesion and endothelial differenti-
ation (Figure S2). Importantly, Notch pathway inhibition with GSI
did not affect BM-PC survival or proliferation (data not shown).
Next, we asked if inhibition of the Notch pathway affected BM-PC
adhesion to ECM by reducing the expression of specific integrins. As
showninFig3andTable1,GSI-treatedBM-PCshowedasignificant
reduction in the expression of alpha3beta1, while beta 3, alpha5 and
alpha v expression levels remained unaffected by GSI treatment.
These results demonstrate that the GSI inhibition of BM-PC
adhesion to different ECM involves the selective down-regulation
of integrins alpha 3 beta 1. Accordingly, siRNAagainst integrin alpha
3 decreased the number of adherent BM-PC (Fig 3 D,E).
Figure 1. BM-PC express Notch pathway ligands/receptors and show increased expression of notch downstream targets during
endothelial differentiation. A. Expression of Notch receptors and ligands in BM-PC was detected by RT-PCR. B. Expression of Notch downstream
targets (Hes 1, Hey 1 and 2) was detected at different time points during BM-PC endothelial differentiation by quantitative real-time PCR. C.
Representative images (6200) of BM-PC at day 20 of culture showing positivity for endothelial lineage specific markers, acetylated LDL, CD31 , Flk-1
and vWF with DAPI nuclear counterstaining in blue. D. Quantification of BM-PC positive cells for acetylated LDL, CD31 , Flk-1 and VWF after 20 days of
culture. Each experiment was performed in triplicate and the mean presented (n=3).
doi:10.1371/journal.pone.0003752.g001
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angiogenic properties in vitro
After showing that Notch inhibition impairs BM-PC adhesion
to ECM and their endothelial differentiation in vitro, we tested
whether it also impaired their angiogenesis-stimulation capacity.
As shown in Figure 4, endothelial cells co-cultured with control
(untreated and DMSO treated) BM-PC for 18 hrs on Matrigel
formed significantly more endothelial branches (quantified as
branch points per high power field) than those resulting from
endothelial cells co-cultured with GSI-treated BM-PC (the effect of
GSI is dose-dependent, Fig 4 C). Since this pro-angiogenic effect
of BM-PC could result from direct contact with endothelial cells or
from paracrine (indirect) stimulation, we next quantified the
number of BM-PC (labelled with ac-LDL) in contact with
Figure 2. Notch pathway early inhibition impairs BM-PC adhesion and spreading to extracellular matrix, reducing the number of
mature cells obtained at the end of the differentiation. A. Expression of Hes 1 and Hey 2 72 h after GSI (10 uM) treatment was detected by RT-
PCR. B. Quantification of adherent BM-PC 72 h after treatment with DMSO, GSI at 10 gMo r1 0mM, on 2% gelatin coated wells. C. Quantification of
adherent BM-PC 48 h after treatment with DMSO and GSI at 10 mM, on 2% gelatin, fibronectin, collagen or laminin coated wells. D. Quantification of
control or GSI BM-PC expressing double EC – lineage specific markers (acLDL/FLK-1 or acLDL/VWF) after 20 days of endothelial differentiation. E.
Representative image (1006) of adherent cells under the different conditions. *P,0,05, **P,0,01. Each experiment was performed in triplicate and
the mean presented (n=3).
doi:10.1371/journal.pone.0003752.g002
Notch Pathway in Bone Marrow
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shown in Figure 4C and quantified in Figure 4D, the majority of
untreated BM-PC are found in contact with the endothelial cells,
in close proximity to branch points; in contrast, GSI-treated BM-
PC are predominantly found throughout the matrigel (Fig 4D).
Therefore, GSI treatment impairs the direct contact between BM-
PC and endothelial cells. Importantly, the total number of BM-PC
in contact with endothelial cells or adherent to the ECM is
Figure 3. Regulation of the Notch pathway interferes with expression levels of integrin sub-units a3 and b1 in BM-PC. A. Expression of
integrin sub-units a3 and b1 determine by real-time PCR on BM-PC after treatment with DMSO or GSI; B. Quantification of a3 expressing BM-PC after
treatment with DMSO or GSI. C. Representative images (2006) of adherent BM-PC imunostained for integrin a3 and b1 in control and GSI treated BM-
PC. D. Quantification of adherent BM-PC after 48 h of transient transfection with siRNA against integrin sub-unit a3 at concentrations of 100 or
200 gM. E. Expression of integrin sub-units a3 determine by real-time PCR on BM-PC after transient transfection with siRNA against integrin sub-unit
a3 at concentrations of 100 or 200 gM. *P,0.01. Each experiment was performed in triplicate and the mean presented (n=3).
doi:10.1371/journal.pone.0003752.g003
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of Notch pathway in regulating BM-PC:endothelial cell adhesion
and BM-PC:ECM adhesion.
Notch pathway inhibition on BM-PC reduces their wound
healing properties in vitro
Since treating BM-PC with GSI impaired their adhesion to
ECM and their capacity to induce endothelial branching, next we
asked whether it also inhibited their wound healing properties. As
shown in Figure 5, the capacity to restore an endothelial
monolayer (in a ‘‘wound healing’’ assay) is significantly improved
upon the addition of control BM-PC to the wounded endothelial
monolayer (Fig 5A). Control BM-PC predominantly adhered to
the exposed ECM and to endothelial cells at the wound edge
(Fig 5B). In contrast, GSI treatment reduced BM-PC adhesion to
ECM and to the endothelial cells at the wound edge (Fig 5B).
Importantly, supernatants obtained from adherent BM-PC also
accelerated wound healing/endothelial monolayer recovery while
supernatant obtained from non-adherent BM-PC failed to do so
(Fig 5C). Taken together, these data suggest that BM-PC may
promote wound healing by direct contact with endothelial cells at
the wound edge and by adhering to the exposed ECM, but also
that paracrine factor(s) released by the adherent BM-PC may
stimulate endothelial cells during the wound healing process.
These results also suggest that Notch pathway inhibition with GSI,
by blocking BM-PC adhesion to ECM and activated endothelial
cells, impairs BM-PC wound healing properties in vitro.
Notch pathway modulation on BM-PC regulates their
angiogenic and their wound healing properties in vivo
After showing that blocking the Notch pathway on BM-PC
impairs their differentiation, adhesion to ECM, angiogenesis and
wound healing promotion in vitro, next we tested the importance of
these observations in a wound healing model in vivo. First, we
verified that wounding induced mobilization of BM-PC to the
peripheral blood of wounded mice (Figure S3).
As quantified and shown in Figure 6A and B, injection of
normal BM-PC to wounded mice improved wound healing
significantly, while BM-PC pre-treated with GSI showed no effect
(mice in this group showed similar rate of wound healing to PBS/
non-injected mice). Importantly, the pro-wound healing property
of BM-PC involved an angiogenesis response at the wound site. As
shown and quantified in Figure 6D,E, mice injected with normal
BM-PC showed a higher microvessel density at the wound site on
days 7 and 14, while those that received BM-PC pre-treated with
GSI showed a similar wound microvessel density to control
(untreated) mice (Data shown for day 14, Fig 6D, E). The increase
in angiogenesis at the wounds after BM-PC injection was detected
using laminin as a microvessel basement membrane marker and
von wilebrand factor as an endothelial marker (Fig 6 D,E) and also
using desmin as a smooth muscle cell marker (data not shown).
These results suggest that BM-PC stimulate endothelial sprouting
and smooth muscle cell recruitment to the wound site. Taken
together, these data suggest that Notch pathway inhibition with
GSI impairs the capacity of BM-PC to promote wound healing
and angiogenesis in vivo. In contrast, activation of the Notch
pathway on BM-PC using soluble Delta-like 4 further improved
their wound healing capacity (Fig 6A and Figure S4), strongly
suggesting that Notch signalling pathway activation on BM-PC
may be used to stimulate wound healing.
GSI-treated BM-PC are found at lower frequencies in
wound tissues
Having demonstrated that Notch pathway inhibition with GSI
impaired the capacity of BM-PC to stimulate angiogenesis and to
promote wound healing in vivo, we asked whether the frequency at
which BM-PC are detected at the wound site might account for
the differences observed. First, we verified that the number of BM-
PC detected at the wound site on days 7 and 14 after wounding is
very low (Fig 7 B). Nevertheless, as exemplified in Figure 7A, GSI
treatment significantly reduced the frequency at which BM-PC are
found in wound tissues. Moreover, as above, activation of the
Notch pathway on BM-PC using soluble Delta-like 4 resulted also
in higher numbers of BM-PC at the wound sites (Fig 7 B). These
results suggest that Notch pathway inhibition by GSI, by impairing
BM-PC adhesion to ECM and to endothelial cells in wounds,
results in a lower frequency of BM-PC at the wound site and
incorporated into neo-vessels.
Discussion
A putative role for BM-derived progenitors in neo-vessel
formation (angiogenesis) and vessel repair has been under intense
scrutiny for the last decade. Numerous studies have argued that
the contribution of this rare and heterogeneous cell population is
essential for vessel activation and repair, although their precise
function or the mechanisms involved remain elusive [22,23].
Direct incorporation of BM-progenitor cells has been extensively
shown in diverse models [24] but the low and variable frequency
at which BM-progenitors are found incorporated into vessels is
suggestive of an indirect (possibly paracrine or justacrine) role
during the neo-angiogenesis processes. Therefore, it is of extreme
importance to understand the mechanisms involved in the
communication between BM-progenitors with angiogenic poten-
tial and endothelial cells at sites of neo-angiogenesis.
In the present work we used lin-sca1+ BM mononuclear cells
(termed BM-PC throughout the manuscript), which under well
defined pro-endothelial differentiation culture conditions [25]
generate over 70–80% mature endothelial cells, to study their
importance in angiogenesis and vessel repair during wound
healing. Previous studies suggested that sca1+ cells are recruited
into sites of vessel damage and ischemia and contribute to vessel
healing and formation [26,27].
We have previously characterized the gene expression profile of
endothelial progenitors under pro-endothelial differentiation
conditions [25], and observed the expression of members of the
Notch pathway. In the present report, we exploited the hypothesis
that this signalling pathway might be involved in the differenti-
ation and, more importantly, in the function of BM-PC during
neo-angiogenesis and vessel repair. The Notch pathway has been
implicated in vasculogenesis in the embryo [14,15,16,17,18], as
well as in adult tumor angiogenesis [28] and wound healing [19],
although BM-derived progenitors were not studied in these
Table 1. Integrin sub-units b3, a5 and av expression on BM-
PC after treatment with DMSO or GSI, as determined by FACS
analysis.
Integrin Integrin expressing cells (%)
DMSO GSI
b3 16% 15%
a5 78% 86%
aV 5,71% 7,2%
doi:10.1371/journal.pone.0003752.t001
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pathway are expressed in BM-PC as well as in activated
endothelial cells [29], we also explored the possibility that this
pathway might promote the communication between the 2 cell
types during physiological angiogenesis.
In the present work, we show expression of Notch1, Jagged 1
and Delta-like 4 on BM-PC and activation of Notch signalling
during endothelial differentiation in vitro. We also demonstrate that
inhibiting this pathway using the gamma secretase inhibitor (GSI)
DAPT reduces the number of mature endothelial cells generated
at the end of the differentiation assay. In addition, we reveal for
the first time the importance of Notch pathway in BM-PC
adhesion to different extracellular matrices. Treatment of BM-PC
with GSI inhibited their adhesion to fibronectin, collagen, laminin
and gelatin, suggesting this effect might be specific of BM-PC
adhesion to the basement membrane. GSI treatment was shown to
significantly reduce the expression of integrins alpha3 beta1 (which
has affinity to the above mentioned ECM components), both at
the transcriptional as well as protein level, and thus regulated BM-
PC adhesion to the ECM. Moreover, siRNA against integrin
alpha3 significantly reduced the adhesion of BM-PC during
endothelial differentiation. There is some literature suggesting that
the Notch pathway modulates integrin activity on endothelial cells
[30] although only at the conformational level and not at the
transcription and translational level. Interestingly, previous studies
have shown that various components of the basement membrane
are expressed in the vessel lumen during tumor [31] angiogenesis
and also during wound healing [4]. These sites probably represent
Figure 4. Notch pathway inhibition on BM-PC reduces their pro-angiogenic properties in vitro. A. Quantitative analysis of Matrigel-
induced tube branching of HUVEC untreated or GSI-treated monoculture and co-cultured with control and GSI-treated BM-PC. Results show the
average number of branch points in 5 high power fields. B. Representative images of HUVEC tube formation in monoculture and co-cultured with
control and GSI treated BM-PC. Phase contrast microscopy (original magnification, 406). C. Quantitative analysis of Matrigel-induced tube branching
of HUVEC untreated or GSI-treated monoculture and co-cultured with control and GSI-treated BM-PC, using different doses of GSI treatment. D.
Representative images of HUVEC tube structures in the presence of control or GSI BM-PC acetylated LDL-FITC labelled (original magnification, 406).
Arrows identify acetylated LDL-FITC labelled control or GSI BM-PC. E. Quantification of control or GSI BM-PC found in or out of endothelial tubular
structures. Results expressed relatively to the total number of BM-PC counted. *P,0.05. Each experiment was performed in triplicate and the mean
presented (n=3).
doi:10.1371/journal.pone.0003752.g004
Notch Pathway in Bone Marrow
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remodelling. Taken together, we suggest that BM-PC may interact
with extracellular matrix exposed at sites of angiogenesis or vessel
repair, and that the Notch pathway is involved in this interaction
by modulating integrin expression. Although we cannot disregard
other, off-Notch, effects in integrin modulation and BM-PC
adhesion and differentiation, our data strongly suggests that this
important signalling pathway is involved. In agreement, in vitro
transfection of BM-PC with a constitutively active form of Notch 4
promoted their adhesion and augmented endothelial differentia-
tion (Figure S2).
Next, we tested the role of the Notch pathway on the ability of
BM-PC to induce endothelial cell activation, migration and tube
formation. Notch inhibition with GSI reduced the capacity of BM-
PC to stimulate endothelial tube formation in vitro, suggesting it
affects their capacity to stimulate angiogenesis. In this tube
Figure 5. Notch pathway inhibition on BM-PC reduces their wound healing properties in vitro. Quantification of HUVEC migration during
wound healing in vitro. HUVEC were cultured alone or in the presence of C/GSI treated BM-PC. Distance was measured in pixels using ImageJ
software. Representative image of HUVEC at the beginning and at the end of the wound healing assay, in the presence of Control or GSI treated BM-
PC. Phase contrast microscopy (original magnification, 2006). B. Quantitative analysis of Control and GSI treated BM-PC localization during HUVEC
wound healing. BM-PC were classified has being on the wound site or over the HUVEC monolayer. Representative confocal image (6400) of BM-PC
stained with acetylated LDL(FITC) and HUVEC (nuclear staining with DAPI). Dashed line represents the HUVEC wound edge. C. Quantitative analysis of
HUVEC migration during wound healing assay. HUVEC were cultured with un-conditioned media or with conditioned media from adherent (Ad) /
non-adherent (Nad) BM-PC. *P,0,05 Each experiment was performed in triplicate and the mean presented (n=3).
doi:10.1371/journal.pone.0003752.g005
Notch Pathway in Bone Marrow
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BM-PC to interact (incorporate?) with endothelial cells during
angiogenesis in vitro. Since endothelial cells during angiogenesis
and wound healing express members of the Notch pathway [29],
we suggest this may be one mechanism by which BM-PC and
activated endothelial cells interact.
Next, we tested the importance of the Notch pathway in the
function of BM-PC in wound healing in vitro and in vivo.W e
demonstrate that normal BM-PC adhere to the ECM at the
wound site and enhance endothelial migration and wound closure.
On the other hand, GSI treatment reduced the adhesion of BM-
PC to extracellular matrix, reduced their interaction with
Figure 6. Notch pathway modulation on BM-PC regulates their angiogenic and their wound healing properties in vivo. A.
Quantification of wound area in Balb-C mice injected with PBS, control BM-PC, GSI BM-PC or sDll4 BM-PC. Area at each time point is expressed
relatively to the area measured immediately after wounding. B. Representative images of the wounds at days 0, 4, 8 and 12. C. Representative
histological images of wounds collected at day 14 after wounding. Hematoxilin and Eosin staining. Scale bar represented. D. Quantification of vessel
basement membrane immunostaining for laminin in the wound tissue of PBS, C-BM-PC or GSI BM-PC injected mice at day 14 post-wounding. E.
Representative image of laminin and VWF immunostaining (* identifies VWF positive staining) in wounds of PBS, C-BM-PC or GSI BM-PC injected mice.
Scale bar represented. *P,0.05 Each experiment was performed in triplicate and the mean presented (n=3).
doi:10.1371/journal.pone.0003752.g006
Notch Pathway in Bone Marrow
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endothelial migration in vitro. Notably, supernatants collected from
adherent BM-PC also improved wound healing, suggesting their
adhesion may result in the production of pro-angiogenic growth
factors such as VEGF, IL-8, among others that promote
endothelial cell activation. Taken together these results show that
Notch activity on BM-PC is necessary (via integrin modulation) for
their ability to recognize and adhere to exposed ECM and
activated endothelial migration. These results also suggest that the
interaction between BM-PC and activated (wounded) endothelial
cells is exerted in a direct/justacrine (Notch pathway) and
indirect/paracrine fashion.
In vivo, intravenous injection of normal BM-PC in wounded
mice increased angiogenesis at the wound site and improved
wound healing, while pre-treatment with GSI reduced BM-PC
homing, resulting in a decreased angiogenic response and delayed
wound healing. These results imply that in the absence of Notch
activation BM-PC lose their wound healing properties in vivo.
Inefficient cutaneous wound healing represents a serious
medical challenge, namely in chronic wounds such as in diabetic
[32,33] and morbid obese patients [34]. Moreover, chronic or
dysfunctional wound healing has been partially attributed to a lack
of an appropriate vascular response [32,33], and also to
dysfunctional BM-derived endothelial progenitors [35,36,37].
Therefore, there has been considerable interest in modulating
the vessels response during impaired wound healing for therapeu-
tic purposes, namely via the use of BM-PC [38,39]. In the present
study, we reveal a crucial and previously undisclosed role of the
Figure 7. Control BM-PC are found at greater frequencies in wounds. A. Representative image of injected C, GSI – or sDll4 treated BM-PC at
the wound site. BM-PC are identified as positive for Y-chromosome probe (white arrow). Immunostainning for collagen IV identifies vessel basement
membrane. Scale bar represented. B. Quantification of BM-PC present at the wound. 10 slides per wound were used for BM-PC quantification.
*P,0.05.
doi:10.1371/journal.pone.0003752.g007
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responses during wound healing in vitro and in vivo.
Taken together, we propose a model which may explain the
involvement of the Notch pathway in the function of BM-PC
during wound healing (Figure 8): 1. Wounding promotes sca1+
BM-derived progenitor mobilization to the peripheral blood; 2.
Activated endothelial cells at the wound site express Notch ligands,
namely Jagged 1 and 2 [29] which may activate Notch signalling
on circulating BM-PC; 3. Notch pathway activation on BM-PC
up-regulates integrin alpha3beta1 and promotes BM-PC adhesion
to extracellular matrix components at the wound site; 4. Adherent
BM-PC stimulate endothelial activation (angiogenesis) in a
justacrine and paracrine manner, resulting in improved wound
healing.
We suggest that modulating the Notch pathway on BM-PC may
be used to stimulate their wound healing potential, and further
foster their use in chronic or delayed wound healing.
Materials and Methods
The procedures involving mice were performed following
Institutional (Instituto Gulbenkian de Ciencia) and National
Guidelines. All experiments were approved by an Institutional
Review Committee.
BM-PC Isolation
To isolate BM-PC, four-to-eight-week-old male BALB/c mice
were sacrificed and their bones collected in DMEM (Gibco)
supplemented with 10%FBS (foetal bovine serum, Sigma-Aldrich,
Germany). Bone-marrow was flushed-off using PBS with 2%FBS
and then ficol (Histopaque-1077, Sigma Diagnostics, St. Louis,
USA) was used to isolate total mononuclear cells (MNC). The
lineage negative (lin-) fraction was isolated using mini-MACS
immunomagnetic separation system (Mylteni Biotec, Bergish
Gladbach, Germany), according to the manufacturer instructions,
and was cultured overnight in RPMI 10%FBS with stem cell factor
(Sigma-Aldrich, 1 ng/ml). Sca-1+ cell isolation was subsequently
done usingmini-MACSimmunomagneticseparationsystem. Purity
of the isolated cells was determined by FACS analysis using anti-
Sca-1 antibodies (BD Pharmigen); isolated BM-PC were used in
further experiments if their purity was above 95%.
Cell Culture and Reagents
Isolated BM-PC were transferred onto 2% gelatine (Sigma-
Aldrich), Fibronectin (10 mg/ml, Sigma-Aldrich), Colagen I
(10 mg/ml, Cell Adhesion) or Laminin (10 mg/ml, Sigma-Aldrich)
coated 24-well plates (1,5610
5 cells/well) and incubated in
endothelial differentiation medium consisting of EBM-2 medium
supplemented with 2% FBS, ECGS (20 mg/ml, Sigma-Aldrich),
Heparin (5 U/ml, Sigma-Aldrich), VEGF (20 ng/ml, Sigma-
Aldrich), HEPES buffer (ph=7,5, 25 mM) and antibiotics.. Every
3 days the medium was supplemented with 1 ml VEGF (20 ng/ml)
and 1 ml Heparin (5 U/ml). Around day 8 of differentiation non-
adherent cells were washed off and new media was added. Cells
were allowed to differentiate for 15–20 days under these
conditions. RNA samples were collected at different time points
and imunofluorescence staining was preformed at the end of the
differentiation assay.
Human umbilical vein endothelial cells (HUVEC), passages 3 to
6, were cultured and maintained following standard procedures
and culture conditions in complete EBM-2 medium (Clonetics).
The c-secretase inhibitor (DAPT, Sigma-Aldrich) was diluted in
Figure 8. Proposed model of the mechanisms modulated by the Notch-Delta pathway on BM-PC during wound healing. 1. Wounded
endothelial cells produce chemoattractant signals that recruit BM-PC into the wound site; 2. As a result of injury/wounding endothelial cells die,
exposing extracellular matrix components in the vessel lumen; activated endothelial cells near the wound edge overexpress ligands of the Notch-
Delta pathway, namely Jagged 1 and 2; BM-PC interact with endothelial cells at the wound site, and as a result of Notch-Delta activation these
recruited cells overexpress integrin alpha3beta1, and bind the exposed extracellular matrix; as a result of BM-PC activation and adhesion, there is an
angiogenesis induction (vessel sprouting) at the wound site. 3. Following angiogenesis activation and re-absortion of the wound tissue/scar, a small
proportion of endothelial cells at the wound site derive from the recruited BM-PC, while the great majority derives from activated pre-existing
endothelial cells. Following the pro-angiogenic response induced by BM-PC, vessel stabilization is promoted by recruitment of smooth muscle cells
(desmin+).
doi:10.1371/journal.pone.0003752.g008
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concentration of 10 mM. In most experiments DMSO was used as
control. Soluble Delta Ligand 4 (BD Pharmigen) was used at a
concentration of 2 mg/ml.
Plasmids, Antisense Oligonucleotides, and Cell
Transfection
The plasmids bearing distinct forms of murine Notch4 were a
gift from Tom Maciag Lab: constitutively active Notch 1 and
Notch4 – CAN1 and CAN4 (C-terminal intracellular domain Int3
cloned into XhoI site of pcDNA3.1 hygro). Plasmid transfections
were preformed using Lipofectamine (Invitrogen) accordingly with
manufacturer’s instructions. The antisense nucleotides (Applied
Biosystems-Ambion) against integrin sub-units a3 (uuccgcugaau-
cauguacgtg) and b1 (ggauaaucayaguaauggctc) were used to
transfect BM-PC using Oligofectamine (Invitrogen) accordingly
with manufacturer instructions.
Reverse-transcription Polymerase Chain Reaction (RT-
PCR)
RNA extraction (Trizol, Invitrogen), cDNA synthesis (Reverse-
transcription with Superscript II reverse transcriptase (Invitrogen))
and oligo (dT) primer (Roche) and RT-PCR were performed
following standard protocols. Primers used in the RT-PCR
reactions were mHes1 (tctacaccagcaacagtgg; tcaaacatctttggcatcac),
mHey1 (tgagctgagaaggctggtac; accccaaactccgatagtcc), mHey2 (tga-
gaagactagtgcaacag; tgggcatcaaagtagccttta), mNotch1 (cggtgaa-
caatgtggatgct; actttggcagtctcatagct), mNotch4 (attgaattcggataaa-
gatgcc; agcgttagcaggtcccagtgac), mDll4 (ctgtccttatggctttgtgg;
gctccttcttctggtttgtg), mDll1 (acagaaacaccagcctccac; gccccaatgatgc-
taacaga),mJagged1(ccagccagtgaagaccaagt;tcagcagaggaaccaggaaa),
mJagged2 (gaggtcaaggtggaaacagt; tgtccaccatcagcagataa), mITGA3
(tgtgtacctgtgtcccctca; atgccggtctgcaagtagtc), mITGB1 (ccaaatcttgcg-
gagaatgt; cattcatcaaatccgttcca). The housekeeping gene used to
normalize the samples was mß-actin (agccatgtacgtagccatcc;
ctctcagctgtggtggtgaa). Each sample was analyzed in duplicate and
each PCR experiment included at least one non-template control
well. PCR products were electrophoresed through 2% agarose gel
and analyzed by staining with ethidium bromide.
Immunofluorescence
Cells were fixed in 2% paraformaldehyde for 15 minutes at
4uC, blocked with PBS+0,1% BSA for 45 minutes at room
temperature and incubated with primary antibody overnight
(diluted in PBS+0,1% BSA+0,1% Triton X-100). Antibodies used
were von Willebrand Factor (vWF, 1:200, A0082, Dako,
Germany), Flk-1 (5 mg/ml, AF644, R&D Biosystems), CD31
(1:100, 553370, BD Pharmigen), P-H3 (1:100, 06-570, Upstate –
Cell Signaling Solutions), VE-cadherin (1:100, sc-6458, Santa
Cruz Biotechnology), integrin a3 (1:100, sc-7019, Santa Cruz
Biotechnology) and integrin b1 (1:100, AF2405, R&D systems,
Inc.). For LDL incorporation cells were cultured in FITC-
conjugated acetylated LDL (ac-LDL, 1:1000, L23380, Invitrogen
– Molecular Probes) during 4 h before fixation. Secondary
antibodies used: anti-rat/goat/rabbit FITC/PE-coupled IgG
(Alexa fluor 488/594, Molecular Probes, US). Cells were
examined by standard fluorescence microscopy using a fluores-
cence microscope (Axioplan Microscope, Zeiss, Germany).
Adhesion Assays
Isolated BM-PC were transferred onto 2% gelatine, Fibronectin
(10 mg/ml), Colagen I (10 mg/ml) or Laminin (10 mg/ml) coated
24-well plates (1,5610
5 cells/well) and incubated in complete
EBM-2 medium. 48 h after seeding, non-adherent cells were
removed (using sterile PBS) and adherent cells were counted in 6
random high power fields (6200). The number of adherent cells
was normalized relatively to the control (gelatine) condition.
In Vitro Wound Healing Assays
HUVEC were harvested by brief trypsin digestion and seeded at a
density of 5610
4cellsper cm
2ona24-wellplate,allowedtogrowtoa
confluent monolayer, and then a scratch wound with a yellow tip
(0,1 mm in diameter) was made at the length of the plate. After the
scratch, the wells were rinsed with PBS to remove detached cells and
EBM-2 medium (2%FBS) was replaced. To determine the effect of
BM-PC on HUVEC monolayer recovery/wound healing, 1,5610
5
BM-PC untreated or treated with DAPT were added. To determine
the effect of secreted factors by adherent or non-adherent BM-PC in
wound healing we added their conditioned medium (collected after
24 h) to wounded HUVEC, using EBM-2 alone as a control. The
total distance migrated by wounded HUVEC was evaluated using
computer image analysis (NIH Image J analyzer) and expressed as
percentage of control (without BM-PC). The distance between the
wound edges was measured immediately after wounding and 8 h
later. The difference between the 2 measurements was considered as
the total distance migrated by the wounded HUVEC. Adherent BM-
PCquantification was obtained by countingthe number of BM-PCat
the wound site (adherent to exposed extracellular matrix or to
HUVEC at the wound edge) versus the number of BM-PC adherent
to HUVEC away from the wound. Data is represented relative to the
wound or monolayer area.
In Vitro Tube Formation Assay
HUVEC were seeded on Matrigel (BD Bioscience) – coated
wells (24 well plate) at a density of 1610
5 cells per well in EBM-2
medium (2%FBS). Untreated, DMSO and DAPT treated BM-PC
were added at a density of 1,5610
5 cells and then incubated for
16–18 h at 37uC. To determine the localization of BM-PC during
the assay, we first incubated these with FITC-conjugated ac-LDL
for 4 h to allow further visualization. After endothelial cell tube
formation was observed the cells were fixed in paraformaldehyde
(2%). Photographs were taken at 106 and 206 magnification
using an Olympus Microscope. Branch quantification was done
using the NIH Image J analyzer and expressed as a percentage of
the control condition (without BM-PC).
In Vivo Wound Healing Model and Wound Closure
Analysis
In vivo wound healing model was established using Balb-SCID
mice. Briefly, female mice, 8 weeks old, body weight 20–33 grams,
were anesthetized with intraperitoneal injection of a combination
of xylazine (10 mg/kg) and ketamine (100 mg/kg). After shaving
the hair, 2 single full thickness, 6-mm diameter excisional wounds
were performed in the dorsolumbar skin with a sterile biopsy
punch. Mice were individually caged. BM-PC were injected in the
tail vein on the day of wound infliction (day 0) and at day 4 post-
wounding. For each injection 2,5610
5 BM-PC untreated or
treated with DAPT or sDll4 were used. Photos were taken every 2
days starting on day 0 and wound area was calculated (P.r1.r2).
Wound area at each time point was represented relatively to the
area obtained at day 0.
Wound histology and Immunohistochemistry
Animals were sacrificed at days 7 and 14 post-wounding. 8 mm
diameter skin biopsy samples centred on the wound bed were
collected, fixed in 10% formalin for a maximum of 48 hours and
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perpendicular to the wound surface, rostral to caudally, with a
500 mm intermission, and stained with haematoxylin and eosin
(H&E). The number of levels analysed ranged from 8–10 per wound.
To visualize blood vessels, sections adjacent to those stained for
H&E were labelled for vWF(1:300, A0082, Dako) and laminin
(1:200; L9393 Sigma-Aldrich, Germany). Briefly, sections were
deparaffinised and immersed in methanol with 0.3% hydrogen
peroxide for 30 minutes. Antigen retrieval was achieved in
protease K for 30 minutes, followed by blocking with 0.1% BSA
in PBS and overnight incubation with the primary antibodies.
Immunolocalization was achieved using biotinylated swine anti-
rabbit IgG antibody (Dako) and peroxidase-conjugated streptavi-
din, 30 min each, and visualized with DAB (Dako) counterstained
with Mayer’s hemalumen (Merck, Germany).
Microvessel density (MVD) was evaluated through laminin and
vWF immunoreactivity. At low power field (640), tissue sections
were screened and 5 areas with the most intense neovasculariza-
tion (hot spots) were selected. Microvessel counts of these areas
were performed at high power field (6200). The mean microvessel
count of the five most vascular areas was taken as the MVD, which
was expressed as the absolute number of microvessels per
0.74 mm2 (6200 field).
ImunoFISH detection of transplanted BMD-VPCs within
wound sections
Wound sections were deparaffinised and antigen retrieval was
achieved in 0,01 M sodium citrate buffer followed by 15 minutes
Pepsin 0,4% digestion. Sections were immunostained for Colagen
IV (1:100, AB769, Chemicon International), and secondary
antibody anti-goat-Alexa 488. Following immunoflorescence, the
sections were hybridized with a probe against the Y chromosome
(Cambio, UK) using a denaturation temperature of 75–80uC for
5 minutes and hybridization temperature of 37uC overnight.
Statistical Analysis
Differences between the experimental groups (cell numbers,
migrated distances, wound size among other parameters) were
calculated using ANOVA or T student test.
Supporting Information
Figure S1 Differentiated BM-PC form tubes on Matrigel. A.
Quantification of tube formation on day 0 or day 20 BM-PC
plated or matrigel for 16 h; *P,0.05 Each experiment was
performed in triplicate and the mean presented (n=3).
Found at: doi:10.1371/journal.pone.0003752.s001 (0.16 MB TIF)
Figure S2 Constitutively active Notch 4 activates the Notch
pathway on transfected BM-PC, promotes their adhesion. A.
Activation of the Notch pathway, as shown by expression of
downstream targets, on BM-PC transfected with constitutively
active Notch 4. B. Constitutively active Notch 4 increases BM-PC
adhesion during in vitro endothelial differentiation.
Found at: doi:10.1371/journal.pone.0003752.s002 (0.06 MB TIF)
Figure S3 Wounds induce mobilization of sca1+ cells in vivo. A,
Quantification of Sca-1+ cells in the peripheral blood of wounded
Balb-SCID mice. Results represented relatively to control/not
wounded at given time points.
Found at: doi:10.1371/journal.pone.0003752.s003 (0.05 MB TIF)
Figure S4 Pre-treatment of BM-PC with soluble Dll4 induces
expression of Notch target genes. A. BM-PC pre-treated with
soluble Dll4 show evidence for transcription of Notch pathway
downstream targets.
Found at: doi:10.1371/journal.pone.0003752.s004 (0.05 MB TIF)
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